[Future directions in clinical development of first-line therapy for diffuse large B-cell lymphoma].

Authors

Koji Kato

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 7. Pages 828-833.

Abstract

For an extended period, R-CHOP therapy was the standard of care for the first-line treatment of diffuse large B-cell lymphoma (DLBCL); nevertheless, approximately 30% of patients experience treatment resistance or relapse, highlighting the limitations of a "one-size-fits-all" treatment strategy. In recent years, however, the development of risk-adapted therapy based on molecular subtype identification and response-adapted therapy using circulating tumor DNA (ctDNA) to detect minimal residual disease has advanced considerably, building on Pola-R-CHP therapy, which became the new standard of care following the POLARIX trial. To further improve the cure rate of DLBCL, it is essential to integrate these molecular pathologies, the tumor microenvironment, and early treatment response assessment to establish personalized first-line treatment strategies that combine novel molecularly targeted drugs and immunotherapy.

PMID:
42543655
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.